| __timestamp | Ligand Pharmaceuticals Incorporated | Sarepta Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 12122000 | 94231000 |
| Thursday, January 1, 2015 | 13380000 | 146394000 |
| Friday, January 1, 2016 | 21221000 | 188272000 |
| Sunday, January 1, 2017 | 26887000 | 166707000 |
| Monday, January 1, 2018 | 27863000 | 401843000 |
| Tuesday, January 1, 2019 | 55908000 | 560909000 |
| Wednesday, January 1, 2020 | 59392000 | 722343000 |
| Friday, January 1, 2021 | 69012000 | 771182000 |
| Saturday, January 1, 2022 | 36082000 | 877090000 |
| Sunday, January 1, 2023 | 24537000 | 877387000 |
Data in motion
In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Sarepta Therapeutics, Inc. and Ligand Pharmaceuticals Incorporated have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, Sarepta's R&D expenses surged by over 830%, reflecting its aggressive pursuit of cutting-edge therapies. In contrast, Ligand's R&D spending grew by approximately 100%, indicating a more measured approach.
Sarepta's R&D investment peaked in 2023, with expenses reaching nearly 880% of its 2014 levels. This substantial increase underscores its focus on developing treatments for rare diseases. Meanwhile, Ligand's R&D spending, although more modest, highlights its strategic partnerships and licensing model. As the biotech landscape evolves, these spending patterns offer insights into each company's innovation strategy and potential future breakthroughs.
R&D Insights: How Novartis AG and Ligand Pharmaceuticals Incorporated Allocate Funds
BeiGene, Ltd. vs Sarepta Therapeutics, Inc.: Strategic Focus on R&D Spending
Research and Development Expenses Breakdown: Sarepta Therapeutics, Inc. vs Lantheus Holdings, Inc.
Research and Development: Comparing Key Metrics for Sarepta Therapeutics, Inc. and Veracyte, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Sarepta Therapeutics, Inc. and Protagonist Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Sarepta Therapeutics, Inc. and MannKind Corporation
Sarepta Therapeutics, Inc. vs Taro Pharmaceutical Industries Ltd.: Strategic Focus on R&D Spending
Research and Development Expenses Breakdown: TG Therapeutics, Inc. vs Ligand Pharmaceuticals Incorporated
Research and Development Expenses Breakdown: Ultragenyx Pharmaceutical Inc. vs Ligand Pharmaceuticals Incorporated
Who Prioritizes Innovation? R&D Spending Compared for PTC Therapeutics, Inc. and Ligand Pharmaceuticals Incorporated
Comparing Innovation Spending: Ligand Pharmaceuticals Incorporated and Evotec SE